Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

Cell signaling pathways orchestrate essential cellular processes from growth to death. In cancer, these critical systems are hijacked, allowing malignant cells to evade control mechanisms and thrive.

The central image depicts currently used strategies for clinical targeting of TGF-β. Below are methods applicable from preclinical screening to clinical practice, including using humanized mouse ...

Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to therapy due to their innate capacity for self-renewal and ...

Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the five-year survival rates for advanced tumors have ...

Scientists at The Wistar Institute and ChristianaCare’s Helen F. Graham Cancer Center & Research Institute have uncovered a ...

Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a cell surface receptor protein called TIE2 as the missing link between two key signaling pathways that ...